TY - JOUR
T1 - CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma
T2 - a practical overview
AU - Mohty, Mohamad
AU - Dulery, Remy
AU - Gauthier, Jordan
AU - Malard, Florent
AU - Brissot, Eolia
AU - Aljurf, Mahmoud
AU - Bazarbachi, Ali
AU - Chabanon, Christian
AU - Kharfan-Dabaja, Mohamed A.
AU - Savani, Bipin N.
AU - Huang, He
AU - Kenderian, Saad S.
AU - Perales, Miguel Angel
AU - Yakoub-Agha, Ibrahim
AU - Nagler, Arnon
N1 - Funding Information:
Conflict of interest MM reports grants and/or lecture honoraria from Janssen, Sanofi, Maat Pharma, JAZZ pharmaceutical, Celgene, Amgen, BMS, Takeda, Pfizer, and Roche, all outside the submitted work. FM reports lecture honoraria from Therakos/Mallinckrodt, Biocodex, Janssen, Keocyte, Sanofi, JAZZ pharmaceutical and Astellas, all outside the submitted work. AB reports honoraria from Abbvie, Novartis, Takeda, Roche, Celgene, Pfizer, Janssen and Amgen and Research support from Novartis, Takeda, Roche, Celgene and Janssen. CC reports honoraria from Kite/Gilead and Novartis. SSK is inventor on patents and royalties licensed to Novartis, Humanigen, and Mettaforge. He receives research support from Kite, Gilead, Novartis, Juno, Cel-gene, Humanigen, Tolero, Lentigen, Sunesis, and Morphosys. He has served on SAB for Humanigen, Kite, and Juno. M-AP reports honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Celgene, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi. IY-A reports honorarium from Gilead/Kite, Celgene, Novartis and Jansse. The other authors did not disclose any relevant conflict of interest in relation to this work Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/relapsed diffuse large B-cell lymphoma. The recognition of the indications for CAR T-cell therapy for patients with aggressive B-cell lymphoma will be discussed, including a review of the algorithms and selection criteria for CAR T-cell therapy and finally, the role of bridging therapy and the timing of CAR T-cell therapy in augmenting chances of a successful outcome.
AB - The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/relapsed diffuse large B-cell lymphoma. The recognition of the indications for CAR T-cell therapy for patients with aggressive B-cell lymphoma will be discussed, including a review of the algorithms and selection criteria for CAR T-cell therapy and finally, the role of bridging therapy and the timing of CAR T-cell therapy in augmenting chances of a successful outcome.
UR - http://www.scopus.com/inward/record.url?scp=85083883799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083883799&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-0892-7
DO - 10.1038/s41409-020-0892-7
M3 - Review article
C2 - 32305998
AN - SCOPUS:85083883799
VL - 55
SP - 1525
EP - 1532
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 8
ER -